LAMISIL ORAL GRANULES Rx
Generic Name and Formulations:
Terbinafine HCl 125mg, 187.5mg; per packet.
Novartis Pharmaceuticals Corp
Indications for LAMISIL ORAL GRANULES:
<4yrs: not recommended. Sprinkle granules on pudding or other soft, non-acidic food and swallow (do not chew); do not use applesauce or fruit-based foods. ≥4yrs: Take once daily for 6 weeks. <25kg: 125mg/day. 25–35kg: 187.5mg/day. >35kg: 250mg/day.
Chronic or active liver disease.
Onychomycosis: confirm diagnosis with nail specimen. Pre-existing hepatic disease or renal impairment (CrCl <50mL/min): not recommended. Perform LFTs prior to and periodically during treatment. Discontinue if hepatic injury, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), taste/smell disturbances, severe neutropenia (neutrophils ≤1000 cells/mm3), thrombotic microangiopathy occurs, or if lupus erythematosus is suspected. Monitor CBCs if immunodeficient. Pregnancy (Cat.B), nursing mothers: not recommended.
Potentiated by cimetidine. Antagonized by rifampin. May potentiate drugs metabolized by CYP2D6 (eg, tricyclic antidepressants, SSRIs, beta-blockers). May be potentiated by CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). Potentiates caffeine. Antagonizes cyclosporine.
Headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbances, nausea, abdominal pain, flatulence, urticaria; also children: nasopharyngitis, pyrexia, cough, upper respiratory infection; rare: hepatotoxicity, depressive symptoms, smell disturbances.
Tabs—30, 100; Packets—14, 42
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness